Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type|Pathology location|Pathology Description|
17-2-1|n/a,n/a|1|n/a|X-rays whole body|11.7|grays|External exposure|300 kV|12 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
17-2-1|n/a,n/a|2|n/a|allogenic Bone marrow transplant||millions of cells injected|Injection, intravenous|allogenic 0.39-2.76 billion mononuclear and 2000-191000 GM-CFC cells|12 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
17-2-2|n/a,n/a|1|n/a|X-rays whole body|11.7|grays|External exposure|300 kV|12 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
17-2-2|n/a,n/a|2|n/a|allogenic Bone marrow transplant||millions of cells injected|Injection, intravenous|allogenic 0.51-1.87 billion mononuclear and 7000-142000 GM-CFC cells|12 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
17-2-2|n/a,n/a|3|n/a|methotrexate|0.25|milligrams per kg animal|not applicable or not supplied|on d 1,3,6, from d11 0.5 mg/kg weekly for 100d|12 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
17-2-3|n/a,n/a|1|n/a|X-rays whole body|11.7|grays|External exposure|300 kV|2 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
17-2-3|n/a,n/a|2|n/a|allogenic Bone marrow transplant||millions of cells injected|Injection, intravenous|allogenic partially heterozyogous 0.68/0.73 billion mononuclear and 68000/73000 GM-CFC cells|2 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
17-2-3|n/a,n/a|3|n/a|methotrexate|0.25|milligrams per kg animal|not applicable or not supplied|on d 1,3,6, from d11 0.5 mg/kg weekly for 100d|2 (0 in ERA)|Dog|Dog, Beagle|Both|Adult|early haemopoietic recovery and haemopoietic function over 2-3 years, age uncertain|No information on individuals available for this study
